Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02511106 · FLOW

Participant flow

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. · Source last updated 2026-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Taken once daily
    id
    FG000
    title
    AZD9291
  2. description
    Taken once daily
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        4
      type
      Lost to Follow-up
    2. reasons
      1. group Id
        FG000
        num Subjects
        24
      2. group Id
        FG001
        num Subjects
        21
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        42
      2. group Id
        FG001
        num Subjects
        82
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        2
      type
      Ongoing study at data cut-off
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        0
      type
      Without specified reason
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        339
      2. group Id
        FG001
        num Subjects
        343
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        337
      2. group Id
        FG001
        num Subjects
        343
      type
      Received Treatment
    3. achievements
      1. group Id
        FG000
        num Subjects
        261
      2. group Id
        FG001
        num Subjects
        234
      comment
      (Study)
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        78
      2. group Id
        FG001
        num Subjects
        109
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
During the 28 day screening period, participants were enrolled based on the presence of at least 1 of the 2 most frequent Epidermal growth factor receptor (EGFR) mutations in their tumor. At the time of enrolment, all participant were required to have central confirmation of EGFR mutation status per eligibility criteria (Exon 19 deletion or L858R mutation).
recruitment Details
A total of 682 Patients were randomized to treatment at 245 Centers in 25 Countries.
Complete source fields
groups
  1. description
    Taken once daily
    id
    FG000
    title
    AZD9291
  2. description
    Taken once daily
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        4
      type
      Lost to Follow-up
    2. reasons
      1. group Id
        FG000
        num Subjects
        24
      2. group Id
        FG001
        num Subjects
        21
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        42
      2. group Id
        FG001
        num Subjects
        82
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        2
      type
      Ongoing study at data cut-off
    5. reasons
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        0
      type
      Without specified reason
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        339
      2. group Id
        FG001
        num Subjects
        343
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        337
      2. group Id
        FG001
        num Subjects
        343
      type
      Received Treatment
    3. achievements
      1. group Id
        FG000
        num Subjects
        261
      2. group Id
        FG001
        num Subjects
        234
      comment
      (Study)
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        78
      2. group Id
        FG001
        num Subjects
        109
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
During the 28 day screening period, participants were enrolled based on the presence of at least 1 of the 2 most frequent Epidermal growth factor receptor (EGFR) mutations in their tumor. At the time of enrolment, all participant were required to have central confirmation of EGFR mutation status per eligibility criteria (Exon 19 deletion or L858R mutation).
recruitment Details
A total of 682 Patients were randomized to treatment at 245 Centers in 25 Countries.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice